enGene (NASDAQ:ENGN) Announces Earnings Results

enGene (NASDAQ:ENGN) issued its quarterly earnings data on Monday. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18), Zacks reports.

enGene Trading Up 0.9%

Shares of ENGN stock traded up $0.08 on Monday, hitting $8.77. The stock had a trading volume of 84,617 shares, compared to its average volume of 404,904. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. enGene has a twelve month low of $2.65 and a twelve month high of $11.14. The company has a fifty day moving average price of $7.89 and a two-hundred day moving average price of $5.76. The firm has a market cap of $566.35 million, a P/E ratio of -4.62 and a beta of -0.28.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Cresset Asset Management LLC bought a new position in shares of enGene during the second quarter worth approximately $36,000. Raymond James Financial Inc. grew its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares in the last quarter. Paloma Partners Management Co bought a new position in enGene during the 2nd quarter worth $38,000. Millennium Management LLC raised its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after acquiring an additional 35,327 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ENGN. Morgan Stanley upped their price objective on shares of enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective (up previously from $30.00) on shares of enGene in a research report on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of enGene in a research note on Wednesday, November 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of enGene in a research note on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.38.

About enGene

enGene, Inc is a clinical?stage biopharmaceutical company focused on the development of gene?based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off?target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.